Evidence map›Paper›PMID 32238195›Full record

ArticleMicrobiome2020

Lung function and microbiota diversity in cystic fibrosis.

Leah Cuthbertson, Alan W Walker, Anna E Oliver, Geraint B Rogers, Damian W Rivett, Thomas H Hampton, Alix Ashare, J Stuart Elborn, Anthony De Soyza, Mary P Carroll and 11 more

Open access · goldAbstract readMulticenter StudyVideo-Audio Media
In one paragraph

Article in Microbiome, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 145 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
145citing papers in PubMed, 2 pooled it
18.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

145 citing papers in PubMed, 2 syntheses or guidelines pooled it, 261 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Journal of bacteriology · 2026
    Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Journal of bacteriology · 2026
    Article
  15. Functional CFTR may be required for Prevotella melaninogenica regulation of epithelial cell defense against Staphylococcus aureus.Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society · 2026
    Article
  16. Article
  17. Review
  18. BioMed research international · 2026
    Review
  19. Frontiers in microbiology · 2026
    Article
  20. Genome sequences of two highly colistin-resistantMicrobiology resource announcements · 2025
    Article

85 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 17 institutions in 3 countries.

Leah CuthbertsonNational Heart and Lung Institute, Imperial College London, London, UK.
Alan W WalkerRowett Institute, University of Aberdeen, Aberdeen, UK.
Anna E OliverNERC Centre for Ecology & Hydrology, Wallingford, UK.
Geraint B RogersSouth Australian Health and Medical Research Institute, Adelaide, Australia.
Damian W RivettDepartment of Natural Sciences, Manchester Metropolitan University, Manchester, UK.
Thomas H HamptonDepartment of Microbiology and Immunology, Geisel School of Medicine at Dartmouth, Hanover, NH, USA.
Alix AshareDepartment of Microbiology and Immunology, Geisel School of Medicine at Dartmouth, Hanover, NH, USA.
J Stuart ElbornNational Heart and Lung Institute, Imperial College London, London, UK.
Anthony De SoyzaInstitute of Cellular Medicine, NIHR Biomedical Research Centre for Ageing, Newcastle University, Newcastle, UK.
Mary P CarrollCystic Fibrosis Unit, Southampton University Hospitals NHS Trust, Southampton, UK.
Lucas R HoffmanSeattle Children's Hospital, Seattle, WA, USA.
Clare LanyonFaculty of Health and Life Sciences, University of Northumbria, Newcastle, UK.
Samuel M MoskowitzDepartment of Pediatrics, Massachusetts General Hospital and Harvard Medical School, Boston, USA.
George A O'TooleDepartment of Microbiology and Immunology, Geisel School of Medicine at Dartmouth, Hanover, NH, USA.
Julian ParkhillWellcome Sanger Institute, Hinxton, Cambridge, UK.
Paul J PlanetPediatric Infectious Disease Division, Children's Hospital of Philadelphia, Philadelphia, PA, USA.
Charlotte C TenebackLarner College of Medicine, University of Vermont, Burlington, VT, USA.
Michael M TunneySchool of Pharmacy, Queen's University Belfast, Belfast, UK.
Jonathan B ZuckermanMaine Medical Center, Portland, ME, USA.
Kenneth D BruceInstitute of Pharmaceutical Science, King's College London, London, UK.
Christopher J van der GastDepartment of Life Sciences, Manchester Metropolitan University, Manchester, UK. C.vanderGast@mmu.ac.uk.
Dartmouth College · USImperial College London · GBManchester Metropolitan University · GBWellcome Sanger Institute · GBDartmouth–Hitchcock Medical Center · USFreeman Hospital · GBHarvard University · USKing's College London · GBNorthumbria University · GBQueen's University Belfast · GBSeattle Children's Hospital · USSouth Australian Health and Medical Research Institute · AUTufts University · USUK Centre for Ecology & Hydrology · GBUniversity Hospital Southampton NHS Foundation Trust · GBUniversity of Pennsylvania · USUniversity of Vermont · US

Funding

cdiGMP regulation of Biofilm FormationR37AI083256 · NIAID · DARTMOUTH COLLEGE · PI O'TOOLE, GEORGE A. · 2014 to 2023
$4.7M
Patient-oriented microbiome and advanced culture approaches to identifying the microbial determinants of chronic pediatric diseaseK24HL141669 · NHLBI · UNIVERSITY OF WASHINGTON · PI Lucas R Hoffman · 2018 to 2026
$929k
In Host Evolution of Nontuberculous Mycobacteria in Cystic FibrosisR21AI144561 · NIAID · CHILDREN'S HOSP OF PHILADELPHIA · PI PLANET, PAUL J · 2020 to 2021
$485k
NHLBI NIH HHS K24 HL141669NIAID NIH HHS R21 AI144561NIAID NIH HHS R37 AI083256Wellcome TrustWellcome Trust WT 098051
6 · The paper itself

Abstract

backgroundChronic infection and concomitant airway inflammation is the leading cause of morbidity and mortality for people living with cystic fibrosis (CF). Although chronic infection in CF is undeniably polymicrobial, involving a lung microbiota, infection surveillance and control approaches remain underpinned by classical aerobic culture-based microbiology. How to use microbiomics to direct clinical management of CF airway infections remains a crucial challenge. A pivotal step towards leveraging microbiome approaches in CF clinical care is to understand the ecology of the CF lung microbiome and identify ecological patterns of CF microbiota across a wide spectrum of lung disease. Assessing sputum samples from 299 patients attending 13 CF centres in Europe and the USA, we determined whether the emerging relationship of decreasing microbiota diversity with worsening lung function could be considered a generalised pattern of CF lung microbiota and explored its potential as an informative indicator of lung disease state in CF.

resultsWe tested and found decreasing microbiota diversity with a reduction in lung function to be a significant ecological pattern. Moreover, the loss of diversity was accompanied by an increase in microbiota dominance. Subsequently, we stratified patients into lung disease categories of increasing disease severity to further investigate relationships between microbiota characteristics and lung function, and the factors contributing to microbiota variance. Core taxa group composition became highly conserved within the severe disease category, while the rarer satellite taxa underpinned the high variability observed in the microbiota diversity. Further, the lung microbiota of individual patient were increasingly dominated by recognised CF pathogens as lung function decreased. Conversely, other bacteria, especially obligate anaerobes, increasingly dominated in those with better lung function. Ordination analyses revealed lung function and antibiotics to be main explanators of compositional variance in the microbiota and the core and satellite taxa. Biogeography was found to influence acquisition of the rarer satellite taxa.

conclusionsOur findings demonstrate that microbiota diversity and dominance, as well as the identity of the dominant bacterial species, in combination with measures of lung function, can be used as informative indicators of disease state in CF. Video Abstract.

Indexed as

MicrobiotaAdultAnti-Bacterial AgentsBacteriaCystic FibrosisDisease ProgressionEuropeFemaleHumansInflammationLungMaleRespiratory Function TestsSequence Analysis, DNASputumUnited StatesAnti-Bacterial AgentsAntibioticsBiogeographyCystic fibrosisDisease severityEcological patternsLung functionLung microbiomeLung microbiotaMicrobial surveillance

Identifiers

PMID32238195
PMCPMC7114784
OpenAlexW3008061956

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.